Universe Pharmaceuticals Inc Revenue Growth Rates (UPC), Current and Historic Growth - CSIMarket
CSIMarket
 


Universe Pharmaceuticals Inc  (NASDAQ: UPC)
 

UPC's Revenue Growth by Quarter and Year

Universe Pharmaceuticals Inc's Revenue results by quarter and year




UPC Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 17,858.73
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 17,858.73

UPCs Annual Revenue
Universe Pharmaceuticals Inc's Revenue in the fiscal year 2025 $ 17,858.73 millions
Universe Pharmaceuticals Inc's Revenue in the fiscal year 2024 $ 23,024.46 millions
Universe Pharmaceuticals Inc's Revenue in the fiscal year 2023 $ 32,308.74 millions
Universe Pharmaceuticals Inc's Revenue in the fiscal year 2022 $ 40.14 millions
Universe Pharmaceuticals Inc's Revenue in the fiscal year 2021 $ 47.98 millions




UPC Revenue fourth quarter 2025 Y/Y Growth Comment
Universe Pharmaceuticals Inc achieved in the fourth quarter 2025, above Company average Revenue surge of 55173.08% year on year, to $ 17,858.73 millions.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 129 other companies have achieved higher Revenue growth. While Universe Pharmaceuticals Inc' s Revenue doubling of 55173.08% ranks overall at the positon no. 2975 in the fourth quarter 2025.




UPC Revenue ( Y/Y Growth %) 2025
2024 2023 2022
4th Quarter December 55173.08 % -19.51 % -16.34 % -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   55173.08 % -19.51 % -16.34 % -

Financial Statements
Universe Pharmaceuticals Inc's fourth quarter 2025 Revenue $ 17,858.73 millions UPC's Income Statement
Universe Pharmaceuticals Inc's fourth quarter 2024 Revenue $ 32.31 millions Quarterly UPC's Income Statement


UPC Revenue (Quarter on Quarter Growth %)

2025
2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   55173.08 % -19.51 % -16.34 % -




Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #130
Healthcare Sector #392
Overall #2975

Revenue Y/Y Growth Statistics
High Average Low
-16.34 % -17.93 % -19.52 %
(Sep 30 2022)   (Sep 30 2023)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #130
Healthcare Sector #392
Overall #2975
Revenue Y/Y Growth Statistics
High Average Low
-16.34 % -17.93 % -19.52 %
(Sep 30 2022)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Universe Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


UPC's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


UPC's IV. Quarter Q/Q Revenue Comment


Universe Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2025)
12 Months Ending
(Sep 30 2024)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Sep 30 2022)
12 Months Ending
Cumulative Revenue 12 Months Ending $ 17,858.73 $ 23,024.46 $ 32,308.74 $ 40.14 $ 0.00
Y / Y Revenue Growth (TTM) -22.44 % -28.74 % 80383.8 % -16.34 % -
Year on Year Revenue Growth Overall Ranking # 2975 # 3098 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -22.44 % -28.74 % 80383.8 % -16.34 % -
Seq. Revenue Growth (TTM) Overall Ranking # 3033 # 3101 # 0 # 0 # 0


Cumulative Revenue growth Comment
Universe Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2024. If the fiscal year would end in Sep 30 2025, Universe Pharmaceuticals Inc's annual Revenue fall would be -22.44% year on year to $17,859 millions.

In the Healthcare sector 391 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2975, from total ranking in previous quarter at 3098.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 134
Healthcare Sector # 392
Overall # 2975

Revenue TTM Y/Y Growth Statistics
High Average Low
-16.34 %
-17.93 %
-19.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 134
Sector # 400
S&P 500 # 3033
Cumulative Revenue growth Comment
Universe Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2024. If the fiscal year would end in Sep 30 2025, Universe Pharmaceuticals Inc's annual Revenue fall would be -22.44% year on year to $17,859 millions.

In the Healthcare sector 391 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2975, from total ranking in previous quarter at 3098.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 134
Healthcare Sector # 392
Overall # 2975

Revenue TTM Y/Y Growth Statistics
High Average Low
-16.34 %
-17.93 %
-19.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 134
Sector # 400
S&P 500 # 3033




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
UPC's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2025
Autolus Therapeutics Plc83,655.17%$ 83,655.172 millions
Guided Therapeutics Inc 58,900.00%$ 58,900.000 millions


About Universe Pharmaceuticals Inc Revenue Growth Rates (UPC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Universe Pharmaceuticals Inc (CIK 1809616).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-009000
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Universe Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.